trending Market Intelligence /marketintelligence/en/news-insights/trending/udNihC37JxdzxWs5JF8BFg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Lilly further hikes FY'19 outlook as new therapies boost Q3 earnings

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Lilly further hikes FY'19 outlook as new therapies boost Q3 earnings

Eli Lilly and Co. said third-quarter earnings increased 5% year over year, and raised its forecast for 2019.

Non-GAAP net income for the period totaled $1.36 billion, or $1.48 per share, up from the year-ago $1.29 billion, or $1.34 per share. The S&P Global Market Intelligence consensus normalized EPS estimate for the quarter was $1.41.

Reported net income rose on an annual basis to $1.25 billion, or $1.37 per share, from $1.15 billion, or $1.12 per share.

The Indianapolis-based pharmaceutical company's revenue increased 3% year over year to $5.48 billion from $5.31 billion. Lilly's top-selling diabetes drug, Trulicity, raked in revenues of $1.01 billion, up 24% on a yearly basis from $816.2 million.

Lilly's third-quarter earnings were boosted primarily by "the growth of our newer medicines and our ability to effectively manage costs while supporting global launches in highly competitive classes and funding our next generation of new therapies," Lilly Chairman and CEO David Ricks said.

Research and development costs reached $1.38 billion in the third quarter, compared to $1.28 billion a year earlier.

For the nine months ended Sept. 30, non-GAAP net income was $3.98 billion, down from $4.01 billion in the year-ago period. Non-GAAP EPS amounted to $4.31, compared to the previous year's $4.13.

Worldwide revenue for the nine-month period rose 2% year over year to $16.21 billion from $15.86 billion.

Lilly further hiked its outlook for 2019 and now anticipates non-GAAP EPS of between $5.75 and $5.85. Previously, the company said it expects adjusted EPS to reach $5.67 to $5.77.

The S&P Global Market Intelligence consensus normalized EPS estimate for 2019 is $5.72.

On a reported basis, Lilly anticipates EPS to be in the range of $8.59 to $8.69, compared to the previous forecast of between $8.58 and $8.68. The company continues to expect full-year revenue to be in the range of $22.0 billion to $22.5 billion.